What is it about?

A novel enantioselective adsorbent was obtained by hybridization of microspherical polystyrene- divinylbenzene (PS-DVB) macroporous particles with eremomycin-stabilized gold nanoparticles (GNPs). Macrocyclic antibiotic eremomycin was used as a stabilization agent to obtain GNPs which were then characterized by transmission electron microscope. The average diameter of obtained nanoparticles is about 16.6 nm. Eremomycin-stabilized nanoparticles were successfully embedded into the porous polymer structure with a resulting chiral selector content of 37.5 ìmol/g. The obtained PS-DVB composite containing GNPs with immobilized eremomycin was studied by scanning electron microscopy and diffuse reflectance spectroscopy. The values of the specific surface area (500 m2/g) and porosity of the adsorbent (0.39 cm3/g) are measured using nitrogen adsorption at low temperatures. The obtained composite material was used as a chiral stationary phase of liquid chromatography. A good separation enantioselectivity to amino acids, their derivatives and beta-blockers under RPC (reversed-phase) and HILIC (Hidrophilic Interaction Liquid Chromatography) mode is demonstrated. The results obtained revealed that the prepared Eremo@GNP@PS-DVB composite is promising for use as a stationary phase in HPLC.

Featured Image

Why is it important?

Enantioselectivity of chiral stationary phases depends on conformation of eremomycin as a chiral selector. An excellent enantioselectivity was obtained when eremomycin was simple adsorbed on the surface of golden nanopoarticles (GNP). This allows use of microspherical hypercrosslinked polystyrene particles containing GNPcoated with eremomycin for HPLC separation of pharmaceuticals.

Read the Original

This page is a summary of: Microspherical polystyrene-divinylbenzene particles hybridized with eremomycin stabilized gold nanoparticles as a stationary phase for chiral liquid chromatography, Industrial laboratory Diagnostics of materials, December 2022, TEST-ZL Publishing,
DOI: 10.26896/1028-6861-2022-88-12-14-20.
You can read the full text:

Read

Contributors

The following have contributed to this page